Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Clasificación en acciones #17996
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Precio por acción
$1.69
Última sincronización: 2026-09-02
Capitalización bursátil
$216.83M
Cambio (1 día)
3.38%
Cambio (1 año)
-66.03%
País
US
Comercio Organogenesis Holdings Inc. (ORGO)

Categoría

Margen Operativo de Organogenesis Holdings Inc. (ORGO)
Margen Operativo al 2026 TTM: 0.00%
Según los informes financieros más recientes y el precio de las acciones de Organogenesis Holdings Inc., el margen operativo actual (TTM) es 0.00%. Al final de 2026, el margen operativo era 0.00%.
Historial de Margen Operativo de Organogenesis Holdings Inc. desde 2026 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
Not enough data for the provided dates.
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
0.00% -
DE
0.00% -
DE
0.00% -
JP
22.93% -
IN
0.00% -
CH
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.